Skip to content

Women in Hematology

US Focus Meeting 2026


📍 Hilton Austin, 500 E 4th St, Austin, TX 78701

🗓️ November 6 - 7, 2026 


Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the Women in Hematology Focus Meeting 2026, to be held on November 6 - 7, 2026.  

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing hematology research and patient treatment.  

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of Women in Hematology US Focus Meeting 2026:

Sanam-Loghavi

Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX


Krina-Patel

Krina Patel, MD
MD Anderson Cancer Center, Houston, TX


Sonali-Smith

Sonali Smith, MD
The University of Chicago Medicine, IL


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
olivia.wright@md-education.com

Agenda & Faculty

November 6, 2026 | Day 1  

08:00 AM
Registration Opens
08:50 AM
Opening Introduction to the Meeting – Tania Lifanova, MD Education

Session I: Myeloid Neoplasms part 1- Advances in Genomic Profiling for Myeloid Malignancies and Their Therapeutic Implications
Moderator: Sanam Loghavi, MD

09:00 AM
Risk-Adapted Management of Clonal Hematopoiesis – Are We There Yet?
Kelly-Bolton
Kelly Bolton, MD
Washington University School of Medicine, St. Louis, MO
09:20 AM
Genomic Mutations in AML: Implications for Risk Stratification and Therapy
Courtney-Dinardo
Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX
09:40 AM
Diagnosis and Frontline Treatment Strategies for ET, PV & MF
Gabriela-Hobbs-2
Gabriela Hobbs, MD
Massachusetts General Hospital, Boston, MA
10:00 AM
Panel Discussion
10:20 AM
Coffee Break

Session II: Myeloid Neoplasms part 2- Emerging Targeted Therapies in Myeloid Disorders
Moderator: Ann-Kathrin Eisfeld, MD

10:40 AM
FLT3 and IDH Inhibitors in Relapsed AML

HC

Hetty Carraway, MD
Cleveland Clinic, Cleveland, OH
11:00 AM
Frontline Therapy for High-Risk MDS
Catherine-Lai
Catherine Lai, MD
Penn Medicine, Philadelphia, PA
11:20 AM
Venetoclax Treatment in MDS: Biological Insights
Simona-Colla
Simona Colla, PhD
MD Anderson Cancer Center, Houston, TX
11:40 AM
Panel Discussion
12:00 PM
Industry Supported Independent Expert Discussion
02:45 PM
Lunch Break

Session III: Lymphoid Neoplasms Part I - Innovations in Immunotherapy for Lymphomas
Moderator: Sonali Smith, MD

01:35 PM
Bispecific Antibodies in Follicular Lymphoma
Loretta-Nastoupil
Loretta Nastoupil , MD
CommonSpirit Mercy Oncology, Durango, CO
01:55 PM
Integration of CAR-T Cell Therapies in Lymphomas
Swetha-Thiruvengadam
Swetha Thiruvengadam, MD
City of Hope, Duarte, CA
02:15 PM
Emerging Modifications to Immunotherapy: the Next Generation in Lymphomas
Sairah-Ahmed
Sairah Ahmed, MD
MD Anderson Cancer Center, Houston, TX
02:35 PM
Panel Discussion
02:55 PM
Coffee Break

Session IV: Lymphoid Neoplasms part 2- Precision Medicine in Lymphoid Malignancies
Moderator: TBD

03:15 PM
T cell Lymphoma Biology and Classification: Clues for Translation to the Clinic
Jennifer-Amengual
Jennifer Amengual, MD
The Herbert Irving Comprehensive Cancer Center, New York, NY
03:35 PM
Biomarker-Driven Treatment Selection in Mantle Cell Lymphoma
Amanda-Cashen
Amanda Cashen, MD
Washington University School of Medicine, St. Louis, MO
03:55 PM
Integrating AI in Lymphoid Disease Prognosis
Siba_El-Hussein
Siba El Hussein, MD
University of Vermont Health, VT
04:15 PM
Panel Discussion
04:35 PM
Adjourn

November 7, 2026 | Day 2

08:30 AM
Registration Opens

Session V: Myeloma
Moderator: TBD

09:00 AM
Intercepting Myeloma Before It Begins: Biology, Risk, and Early Intervention

US

Urvi Shah, MD
Memorial Sloan Kettering Cancer Center,
New York, NY
09:20 AM
Quadruplets as the New Standard: Precision Escalation or Overtreatment?

NJ

Nisha Joseph, MD
Emory Winship Cancer Institute, Atlanta, GA
09:40 AM
The BCMA Saturation Point: Sequencing, Resistance, and Retreatment

SS

Surbhi Sidana, MD
Stanford Medicine, CA
10:00 AM
Panel Discussion
10:20 AM
Coffee Break

Session VI: Topic TBD
Moderator: TBD

10:40 AM
From Cytogenetics to Immune Fitness: Biomarkers That Change Practice
Doris-Hansen-1
Doris Hansen, MD
Moffitt Cancer Center, Tampa, FL
11:00 AM
Expanding the Target Map: GPRC5D, FCRH5, and Dual-Antigen Strategies
Leyla-Shune
Leyla Shune, MD
University of Kansas Medical Center, Kansas City, KS
11:20 AM
Reprogramming Immunity: CELMoDs, Trispecifics, and In Vivo CAR-T
Krina-Patel
Krina Patel, MD
MD Anderson Cancer Center, Houston, TX
11:40 AM
Panel Discussion
12:00 AM
Lunch Break
12:50 PM
Industry Supported Independent Expert Discussion

Session VII: Chronic Lymphocytic Leukemia - Advances in Targeted and Combination Therapies
Moderator: Jennifer Woyach, MD 

01:35 PM
BTK Inhibitors in Frontline CLL Management

JB

Jacqueline C. Barrientos, MD
Icahn School of Medicine at Mount Sinai, New York, NY
01:55 PM
BCL2 Antagonists for Relapsed CLL
Danielle-Brander
Danielle M. Brander, MD
Duke University, Durham, NC
02:15 PM
Emerging Bispecifics and CAR-T in High-Risk CLL

DS

Deborah Stephens, MD
UNC School of Medicine, Chapel Hill, NC
02:35 PM
Panel Discussion
02:55 PM
Coffee Break

Session VIII: Acute Lymphoblastic Leukemia - Advances Classification and in Targeted Therapies
Moderator: Jennifer Woyach, MD 

03:15 PM
Novel Therapies for Relapsed/Refractory B-ALL
Marlise-Luskin
Marlise Luskin, MD
Dana-Farber Cancer Institute, Boston, MA
03:35 PM
Advances in Immunotherapy for T-ALL

LM

Lori Muffly, MD
Stanford Medicine, CA
03:55 PM
CAR-T Cell Therapy in B-ALL and T-ALL

SM

Shannon L. Maude, MD
Children’s Hospital of Philadelphia, PA
04:15 PM
Panel Discussion and Q&A 
04:35 PM
Adjourn

Olivia Wright
Project Manager

How long has Olivia Wright been in the business?

Olivia Wright has been with MD Education since 2025

About Olivia Wright

As an Assistant Project Manager, I support the delivery of educational events and projects at MD Education, working closely with the project management team to ensure smooth coordination and consistently high-quality execution. With a strong background in organisation and communication, I take pride in maintaining a detail-oriented approach to my work. I am committed to delivering to a high standard and value the opportunity to be part of a team dedicated to advancing clinical education.

Screenshot 2026-01-19 at 16.10.11